ABSTRACT
Multiple summer events, including large indoor gatherings, in Provincetown, Massachusetts (MA), in July 2021 contributed to an outbreak of over one thousand COVID-19 cases among residents and visitors. Most cases were fully vaccinated, many of whom were also symptomatic, prompting a comprehensive public health response, motivating changes to national masking recommendations, and raising questions about infection and transmission among vaccinated individuals. To characterize the outbreak and the viral population underlying it, we combined genomic and epidemiological data from 467 individuals, including 40% of known outbreak-associated cases. The Delta variant accounted for 99% of sequenced outbreak-associated cases. Phylogenetic analysis suggests over 40 sources of Delta in the dataset, with one responsible for a single cluster containing 83% of outbreak-associated genomes. This cluster was likely not the result of extensive spread at a single site, but rather transmission from a common source across multiple settings over a short time. Genomic and epidemiological data combined provide strong support for 25 transmission events from, including many between, fully vaccinated individuals; genomic data alone provides evidence for an additional 64. Together, genomic epidemiology provides a high-resolution picture of the Provincetown outbreak, revealing multiple cases of transmission of Delta from fully vaccinated individuals. However, despite its magnitude, the outbreak was restricted in its onward impact in MA and the US, likely due to high vaccination rates and a robust public health response.
Competing Interest Statement
Competing interests: P.C.S. is a co-founder of, shareholder in, and scientific advisor to Sherlock Biosciences, Inc., as well as a Board member of and shareholder in Danaher Corporation. J.E.L. has received consulting fees from Sherlock Biosciences. A.P. is a Venture Partner at Google Ventures. Other authors report no competing interests.
Funding Statement
This work was sponsored by the Centers for Disease Control and Prevention COVID-19 baseline genomic surveillance contract sequencing (75D30121C10501 to Clinical Research Sequencing Platform, LLC), a CDC Broad Agency Announcement (75D30120C09605 to B.L.M), National Institute of Allergy and Infectious Diseases (U19AI110818 and U01 AI151812 to P.C.S.), the Rockefeller Foundation (2021HTH013 to B.L.M. and P.C.S.), and the Bill and Melinda Gates Foundation (INV-002717 to B.L.M.), as well as support from the Doris Duke Charitable Foundation (J.E.L.), the Howard Hughes Medical Institute (P.C.S.), and the National Human Genome Research Institute (K99HG010669 to S.K.R.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was reviewed and approved by the Massachusetts Department of Public Health Institutional Review Board and covered by a reliance agreement at the Broad Institute.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
We deposited genomes (Genbank), metadata (BioSample), and raw reads (SRA) to NCBI under BioProject PRJNA715749. All genomes produced in the present study are also available on GISAID.
